Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Voyageur Secures First International Sales Contract worth US$1.9 Million (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Equillium Inc EQ

Healthcare Biotechnology
Equillium, Inc. is a clinical-stage biotechnology company. It is engaged in developing novel therapeutics to treat severe autoimmune and inflammatory disorders with high unmet medical need. The Company’s pipeline consists of immunomodulatory assets and a product platform targeting immuno-inflammatory pathways. The Company’s EQ101 is a selective tri-specific cytokine inhibitor targeting IL-2, IL... see more

Recent & Breaking News (NDAQ:EQ)

Equillium Announces Additional Patient Data at ASH 2021 Demonstrating Continued Positive and Durable Clinical Responses in Acute Graft-Versus-Host Disease Patients Treated with Itolizumab

Business Wire December 13, 2021

Equillium Reports Third Quarter 2021 Financial Results and Provides Clinical Development Updates

Business Wire November 10, 2021

Equillium to Present at Two Upcoming Investor Conferences

Business Wire November 9, 2021

Equillium Presents Clinical Data from EQUALISE Phase 1b Study in Lupus Patients at the American Society of Nephrology Annual Meeting

Business Wire November 5, 2021

Equillium Presents Interim Safety Data from First Cohort of Asthma Patients in Phase 1b EQUIP Study at the American College of Allergy, Asthma & Immunology Meeting

Business Wire November 5, 2021

Equillium Announces Two Abstracts Accepted for Presentation at the 63rd ASH Annual Meeting and Exposition

Business Wire November 4, 2021

Equillium Announces Interim Safety Data and Reduction in Proteinuria for Lupus Patients Treated with Itolizumab in the EQUALISE Study Presented at the ACR Annual Meeting

Business Wire November 2, 2021

Equillium Announces Two Abstracts Accepted for Presentation at the Upcoming Virtual 2021 American Society of Nephrology Annual Meeting

Business Wire October 18, 2021

Equillium Announces Multiple Abstracts Accepted for Presentation at ACR Convergence 2021

Business Wire September 30, 2021

Equillium to Present at the Cantor Fitzgerald Virtual Global Healthcare Conference

Business Wire September 22, 2021

Equillium to Present at the H.C. Wainwright 23rd Annual Global Investment Conference

Business Wire September 8, 2021

Equillium Announces Update to EQUALISE Study of Itolizumab in Patients with Systemic Lupus Erythematosus and Lupus Nephritis

Business Wire August 11, 2021

Equillium Reports Second Quarter 2021 Financial Results and Provides Clinical Development Update

Business Wire August 10, 2021

Equillium to Present at the BTIG Virtual Biotechnology Conference

Business Wire August 5, 2021

Equillium Announces Plans to Initiate Phase 3 Pivotal Study of Itolizumab in First-line Treatment of Acute Graft-Versus-Host Disease Following End-of-Phase 1 Meeting with the FDA

GlobeNewswire July 12, 2021

Equillium Presents Data on Target Engagement and Modulation of CD6 on T Cells with Itolizumab at the International Society for Advancement of Cytometry

GlobeNewswire June 10, 2021

Equillium to Present at the JMP Securities Life Sciences Conference

GlobeNewswire June 9, 2021

Equillium to Collaborate with Oxford University and Kennedy Institute of Rheumatology to Investigate Role of the CD6-ALCAM Pathway and Itolizumab in Rheumatic Diseases

GlobeNewswire June 7, 2021

Equillium to Host Conference Call Following Presentation of Data from the EQUATE Study in Acute Graft Versus Host Disease at the EHA2021 Virtual Congress of the European Hematology Association on June 11

GlobeNewswire June 3, 2021

Equillium to Present at the Jefferies Virtual Healthcare Conference

GlobeNewswire May 26, 2021